Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results, Beats Estimates By $0.23 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNY) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The business’s revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.40) EPS.

Alnylam Pharmaceuticals Trading Up 1.3 %

ALNY stock traded up $2.02 during mid-day trading on Friday, reaching $152.33. The company’s stock had a trading volume of 452,157 shares, compared to its average volume of 763,489. The stock has a market cap of $19.19 billion, a PE ratio of -42.22 and a beta of 0.41. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The company’s 50 day moving average is $149.76 and its two-hundred day moving average is $165.25.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ALNY shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 13th. JPMorgan Chase & Co. boosted their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $215.88.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.